SCHEMBL14938898

SCHEMBL14938898

CC(C)C(N)C(=O)NC(CCCCNC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
GAA P10253 1/20 0.53
TDP1 Q9NUW8 5/20 0.46
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
ATM Q13315 2/20 0.43
MAPT P10636 2/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
NPSR1 Q6W5P4 4/20 0.41
POLB P06746 3/20 0.41
CAPN1 P07384 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MMP1 P03956 1/20 0.40
MMP3 P08254 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19776667 1.00 MEN1 (0.53) MEN1KMT2AGAATDP1CA1
SCHEMBL14938896 1.00 MEN1 (0.53) MEN1KMT2AGAATDP1CA1
SCHEMBL16862479 1.00 MEN1 (0.53) MEN1KMT2AGAATDP1CA1
SCHEMBL21906253 0.96 MEN1 (0.50) MEN1KMT2AGAATDP1CA1
SCHEMBL26527825 0.96 MEN1 (0.58) MEN1KMT2AGAATDP1CA1
SCHEMBL24642843 0.90 CAPN1 (0.49) MEN1KMT2AGAACA1CA2
SCHEMBL29714777 0.89 CA1 (0.47) MEN1KMT2AGAATDP1CA1
SCHEMBL30898863 0.88 MEN1 (0.56) MEN1KMT2AGAATDP1CA1
SCHEMBL16424876 0.88 MEN1 (0.56) MEN1KMT2AGAATDP1CA1
SCHEMBL16485196 0.88 CA1 (0.48) MEN1KMT2AGAATDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114917361-A Antibody Drug Conjugates (ADC) and antibody prodrug conjugates (APDC) with enzyme cleavable groups 拜耳医药股份有限公司 2022-08-19 CN disclosed
CN-107635586-B Antibody-drug conjugates (ADC) of KSP inhibitors with aglycosylated anti-TWEAKR antibodies 拜耳医药股份有限公司 2021-09-24 CN disclosed
US-10344261-B2 Immunomodulatory conjugates ASCEND BIOPHARMACEUTICALS LTD (AU) 2019-07-09 US disclosed
US-20150030626-A1 IMMUNOMODULATORY CONJUGATES Ascend Biopharamaceuticals Ltd (AU) 2015-01-29 US disclosed
EP-2776070-A1 IMMUNOMODULATORY CONJUGATES Ascend Biopharmaceuticals Ltd (AU) 2014-09-17 EP disclosed
WO-2013067597-A1 IMMUNOMODULATORY CONJUGATES ASCEND BIOPHARMACEUTICALS PTY LTD (AU) 2013-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344261-B2 Immunomodulatory conjugates CLEC4M, TLR3, CD74 MEN1 965/4885KMT2A 1035/4885GAA 414/4885
US-20150030626-A1 IMMUNOMODULATORY CONJUGATES CLEC4M, TLR3, CD74 MEN1 965/4885KMT2A 1035/4885GAA 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.